Eton Pharmaceuticals (ETON) Cash & Current Investments (2017 - 2026)

Eton Pharmaceuticals has reported Cash & Current Investments for 9 years, with the latest figure at $25.9 million in Q4 2025.

• Quarterly Cash & Current Investments rose 73.69% year-over-year to $25.9 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $25.9 million (up 73.69% YoY) and the FY2025 annual result came in at $25.9 million, up 73.69% from the prior year.
• Cash & Current Investments eased to $25.9 million in Q4 2025 per ETON's latest filing, from $37.1 million in the prior quarter.
• Over five years, Cash & Current Investments peaked at $37.1 million in Q3 2025 and troughed at $13.4 million in Q3 2022.
• A 5-year average of $20.3 million and a median of $19.0 million in 2024 frame the typical range for Cash & Current Investments.
• The sharpest annual moves came in 2021 and 2022: Cash & Current Investments jumped 209.72% in 2021, then plunged 41.09% in 2022.
• Over 5 years, Cash & Current Investments stood at $14.4 million in 2021, then rose by 13.18% to $16.3 million in 2022, then jumped by 31.17% to $21.4 million in 2023, then slumped by 30.17% to $14.9 million in 2024, then soared by 73.69% to $25.9 million in 2025.
• According to Business Quant data, Cash & Current Investments over the past three periods registered $25.9 million, $37.1 million, and $25.4 million for Q4 2025, Q3 2025, and Q2 2025 respectively.